RESEARCH ARTICLE

Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis

Sarah Keller1*, Annette Aigner2, Roman Zenouzi3, Anne C. Kim4, Arnoud Meijer5, Sören A. Weidemann6, Till Krech6, Ansgar W. Lohse3, Gerhard Adam1, Christoph Schramm3, Jin Yamamura1

1 Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, 2 Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, 3 1st Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, 4 Department Stroke and Neurovascular Imaging, The Permanente Medical Group, San Francisco, California, United States of America, 5 Department of Radiology, Leiden University Medical Center (LUMC), Leiden, The Netherlands, 6 Institute of Pathology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

* s.keller@uke.de

Abstract

Objective

To evaluate magnetic resonance imaging (MRI) parameters T2 signal, contrast enhancement (CE), and relative liver enhancement (RLE) of extracellular gadolinium-based contrast agent (GBCA)-enhanced MRI as a marker for hepatic fibrosis and inflammation in patients with primary sclerosing cholangitis (PSC).

Methods

3.0-Tesla MRI scans and liver biopsies of 40 patients (41.2 ± 17.1 years) were retrospectively reviewed. Biopsies were obtained within a mean time of 54 ± 55 days to MRI scans and specimens were categorized according to Ishak modified hepatic activity index (mHAI) and Scheuer staging of fibrosis. T2 signal (N = 40), CE alterations (N = 29), and RLE (N = 29) were assessed by two raters. Mixed-effects regression models were applied to estimate the association between histopathology and MRI parameters.

Results

No significant association was observed between T2 signal or CE alterations with stages of fibrosis or mHAI grading. Regression models revealed significant positive associations of portal venous phase RLE with mHAI grade ≥ 7 points [β = 25.5; 95% CI (2.53; 48.62); p = 0.04] and delayed phase RLE with stages of fibrosis [stage 2: β = 35.13; 95% CI (11.35; 58.87); p = 0.007; stage 3/4: β = 69.24; 95% CI (45.77; 92.75); p < 0.001]. The optimal cut-off value of 66.6% delayed phase RLE distinguished fibrosis stages 0–2 from 3–4 with a
sensitivity of 0.833 and specificity of 0.972. Inter-rater reliability (IRR) for quantification of RLE was ‘excellent’ \((r = 0.90–0.98)\). IRR was ‘substantial’ for detection of T2 signal in the right liver lobe (RL) \((\text{Kappa} = 0.77)\) and ‘almost perfect’ for T2 signal of the left liver lobe (LL) and CE of both lobes \((\text{Kappa} = 0.87–1.0)\).

**Conclusion**

The simple and reproducible method of RLE quantification on standard extracellular GBCA-enhanced MRI may provide a correlate measure of advanced stages of hepatic fibrosis and potentially also inflammation in PSC patients, if validated in larger cohorts.

**Introduction**

Primary sclerosing cholangitis (PSC) is a cholestatic liver disease characterized by chronic inflammation, subsequent obliteratorive periductal destruction and fibrosis, culminating in secondary biliary cirrhosis and liver failure [1–3].

Quality of life and patient survival are reduced due to a markedly increased risk of cholangiocarcinoma, hepatocellular carcinoma, and colorectal cancer [4, 5]. The incidence of PSC varies geographically, where the reported incidence in the United States, Northern Europe, and Canada ranges from 0.9 to 1.3 per 100,000, and is less than 0.1 per 100,000 in Southern Europe and Asia [6, 7].

The diagnosis of PSC is usually based on biochemical, clinical, and cholangiographic findings using magnetic resonance cholangiopancreatography (MRCP) [8–10]. Histopathological examination is not standard procedure in current guidelines [9]. However, histopathological scoring systems for inflammatory activity and fibrosis can provide useful information about disease activity and stage of liver fibrosis as well as the patient’s prognosis [11].

PSC is unique in its patchy distribution of liver parenchyma inflammation and confluent fibrosis, increasing the risk of sampling error, as biopsy covers only a tiny fraction of the liver (roughly 1/50,000th) [12]. Furthermore, its invasive nature carries risks such as hemorrhage with a fatality rate of up to 0.03% [13]. Non-invasive tools to quantify fibrosis and liver inflammation are urgently needed to assess treatment response in clinical trials.

Magnetic resonance imaging (MRI) is recommended as the diagnostic modality of choice in PSC [14]. In recent years elaborate MRI sequences for diagnosis and staging of fibrosis, such as MR elastography (MRE) have been investigated. MRE non-invasively quantifies the stiffness of liver in later stages of fibrosis (2 vs. 3 vs. 4) but may be confounded by a variety of factors, which can alter liver stiffness such as hepatic steatosis, cholestasis, and portal hypertension [15–17].

Conventional extracellular gadolinium-based contrast agent (GBCA)-enhanced MRI and MRCP are routinely performed in PSC patients for diagnosis and surveillance of malignancy and dominant biliary strictures [18–20]. An additional imaging feature of GBCA-enhanced MRI is the evaluation and quantification of inflammation and progressive fibrosis using either hepatocyte-specific or extracellular GBCA [21, 22]. Abnormal perfusion patterns using extracellular GBCA have been observed in patients with hepatic inflammation in acute [23, 24] and chronic liver diseases [25, 26] with distinct patterns of fibrosis, inflammatory cell infiltrates, necrosis, and micro- or macronodular cirrhosis. A multiphase extracellular GBCA-enhanced MRI study performed by Martin et al. [27] in patients with hepatitis reported a high correlation of delayed phase contrast enhancement with histological staging of fibrosis \((r = 0.96; 95\%\)
confidence interval (CI) 0.941–0.976), but not between arterial/venous/delayed phase imaging and histological grades of inflammation. In recent years dynamic contrast-enhanced (DCE) MRI using the hepatocyte-specific contrast agent gadoxetic acid has been proposed to assess hepatic function as a surrogate for hepatic fibrosis, by quantifying parameters like hepatocellular uptake rate, input relative blood flow, and mean transit time (MTT) using deconvolutional analyses [28]. For example Nilsson et al. [28] described a significant lower global median hepatic extraction fraction (HEF) and global median MTT, and larger parenchymal volume (p < 0.05) in patients with liver cirrhosis compared to healthy controls. Norén et al. [29] reported significant intergroup differences in hepatic contrast uptake rate (K(hep)) between mild (F0/1) and advanced (F3/4) histopathological stages of fibrosis (p = 0.05) in N = 38 patients with various liver diseases. However the routine clinical application of functional DCE imaging is limited due to extensive and time-consuming post-processing, as well as to several confounding factors such as cardiac status, hepatic congestion, and inflammation [30].

The aim of the present study was to retrospectively evaluate the quantitative and qualitative MRI parameters T2 signal, contrast enhancement (CE) and relative liver enhancement (RLE) of extracellular GBCA-enhanced MRI as a marker for hepatic fibrosis and inflammation in patients with PSC using liver histopathology as gold standard.

Methods

Subjects

The retrospective study was approved by the Ethics committee of the Hamburg Medical Association. 40 patients with known PSC according to EASL guidelines were assessed between January 2008 and January 2015. Written informed consent for general use of data and standard MRI was acquired from each patient. Patients with previous liver surgery, a history of hepatocellular carcinoma or cholangiocarcinoma, and a change of the therapeutic regimen for PSC disease within the time interval of MRI scan and liver biopsy, were excluded. All patients underwent liver biopsy of the right liver lobe (RL) and/or the left liver lobe (LL) within 6 months (mean ± standard deviation 54 ± 55 days, range 0–180 days) to the MRI scan.

Out of 40 patients, N = 29 patients received intravenous contrast agents. The administration of contrast agents was avoided in N = 8 patients due to renal impairment (glomerular filtration rate < 30 ml/min) and N = 1 patient due to relevant allergic reactions after previous contrast administration. Two patients received a hepatocyte-specific contrast agent and were excluded from contrast-based analysis (CE and RLE).

Liver biopsy and histopathological examination

Because of previous reports of higher sensitivity for detection of fibrosis and lower complication rate with mini-laparoscopic versus percutaneous performed liver biopsies [31], all samples were acquired by mini-laparoscopy as previously described [32]. The location of biopsy was documented in the laparoscopy report and retrospectively allocated according to liver segments defined by Strasberg et al. [33]. The histopathology was evaluated by two pathologists with 5 years (SW) and 11 years (TK) experience in histopathological grading/staging of liver biopsies separately for the RL and LL, using the Ishak modified hepatic activity index (mHAI) and Scheuer fibrosis staging of chronic hepatitis [34]. The mHAI was chosen since there is no grading system specific for PSC inflammatory activity. The mHAI grades four major characteristics (sum 18 points) of necroinflammatory tissue changes (A: periportal or perisepal interface hepatitis; B: confluent necrosis; C: focal lytic necrosis, apoptosis and focal inflammation; D: portal inflammation). In autoimmune hepatitis, a cut-off value of mHAI points ≥ 3 represents significant liver inflammation [35], and was found to indicate immunosuppressive...
treatment in patients with PSC in a previous retrospective multicenter study [36]. The staging system developed by Scheuer et al. [37] was used for architectural staging of liver fibrosis and cirrhosis. This classification system defines liver tissue without architectural changes (0 points) to cirrhosis (4 points) [37].

**MR imaging technique**

MRI was performed on a 3.0-Tesla scanner (Ingenia, Philips Medical Systems, Best, The Netherlands) with an eight-channel body coil. Axial T2-weighted imaging was performed covering the whole liver and subjects were asked to hold their breath at the same depth during each acquisition. Baseline and contrast-enhanced dynamic images were acquired before and after intravenous injection of 0.1 mmol/kg (0.2 ml/kg) of gadopentetate dimeglumine (Magnevist Bayer Healthcare, Leverkusen, Germany) into the antecubital vein using a power injector (Medrad, Spectris Solaris, EP Injection System, Bayer Healthcare, Berlin, Germany) at an infusion rate of 2 mL/s, followed immediately by a bolus of 20 mL saline (NaCl 0.9%) at the same infusion rate. A fat saturated T1-weighted imaging of the whole liver in axial orientation was performed before contrast injection and followed by repetitive sequences 10 seconds (arterial phase), 90 seconds (portal venous phase) and 5 minutes (delayed phase) after injection. MRI sequence details are specified in Table 1.

**Image analysis**

MRI data were analyzed and rated by two independent radiologists (SK and JY) with 4 and 10 years experience in abdominal MRI, respectively, blinded to patients’ history, histology, and laboratory findings. Images with binary results between both raters were assessed by a third rater (AM) with 6 years experience in abdominal imaging.

According to the liver segment used for laparoscopically performed biopsy, axial and coronal T2-weighted images and contrast-enhanced axial T1-weighted images were analyzed regarding the visual aspect of T2 signal alterations (T2 hyperintensity = 1; absence of significant T2 hyperintensity = 0) and increased contrast enhancement (CE) (increased CE = 1; absence of significant CE = 0) of the portal venous and delayed phase imaging (Fig 1).

To avoid sampling errors, three regions of interest (ROI), with a mean size of 1.8 cm$^2$ ($\pm$ 0.7 cm$^2$ standard deviation) were drawn on adjacent slices of the non-enhanced T1-weighted axial imaging of the biopsied liver lobe. Each ROI was then copied exactly to the portal venous and delayed phase axial contrast-enhanced T1-weighted image. The signal intensity (SI) of the copied ROIs was assessed to derive three replicate values, which were then averaged for further assessment (Fig 2).

Mean SI obtained from the ROIs of the T1-weighted non-enhanced (baseline) and contrast-enhanced (portal venous and delayed phase) images were used to calculate the RLE using the following algorithm, adapted for extracellular GBCA and published previously by Nolz [36].

| Sequence       | Plane   | Field of view (mm) | Flip angle (˚) | TE (ms) | TR (ms) |
|----------------|---------|--------------------|----------------|---------|---------|
| T1w (fat saturated) | axial   | 340x340            | 10             | 1.6     | 3.3     |
| T2w             | axial   | 340x340            | 90             | 80      | 1250    |
| T2w             | coronal | 340x340            | 90             | 80      | 875     |

Contrast agent: Gadopentetate dimeglumine i.v. 0.1 mmol/kg (0.2 ml/kg).

Image acquisition before (non-enhanced), 10 seconds (arterial), 90 seconds (portal venous), and 5 minutes (delayed) after injection.

https://doi.org/10.1371/journal.pone.0193929.t001
et al. [38]:

\[
RLE = \left( \frac{SI_{\text{enhanced}} - SI_{\text{non-enhanced}}}{SI_{\text{non-enhanced}}} \right) \times 100
\]

Where \( SI_{\text{enhanced}} \) is the signal intensity either of the portal venous or the delayed phase contrast-enhanced imaging, and \( SI_{\text{non-enhanced}} \) is the signal intensity of the baseline image.

Laboratory data

Relevant demographic and clinical data, as well as serum liver function tests of disease activity (alkaline phosphatase (AP), alanine-amino-transferase (ALT), aspartate-amino-transferase (AST), Immunoglobulin G (IgG), gamma-glutamyl transferase (γGT)) were obtained from the patients’ records at the time point closest to MRI examination (mean 25.6 ± 27.6 days, range 0–125 days).

Statistical analysis

To quantify the inter-rater reliability (IRR) of the two observers we used Cohen’s Kappa with its 95% confidence interval (CI) [39]. The Kappa coefficient amplitude was 0 to 1, where the agreement strength was interpreted using guidelines by Landis and Koch [40]: <0, poor; 0.01
to 0.20, slight; 0.21 to 0.4, fair; 0.41 to 0.6, moderate; 0.61 to 0.80, substantial; 0.81 to 1, almost perfect. For binary results of T2 signal and CE rating, the results of an independent third rater were used.

For continuous variables (RLE portal venous and delayed) Pearson correlation coefficients (r) and Bland-Altman plots were used to assess the IRR of the two observers. The criteria of Portney and Watkins [41] were used to judge the strength of the correlation coefficients, as follows: little to no relationship (r ≤ 0.25), fair degree of relationship (r = 0.26 to 0.50), moderate-to-good relationship (r = 0.51 to 0.75), and good-to-excellent relationship (r ≥ 0.76).

The dependencies in the data for measurements in the RL and LL were quantified descriptively for mHAI and fibrosis stage. Due to these dependencies we used mixed-effects logistic and linear regression models with a random intercept by patient to derive effect estimates and 95% confidence intervals (CI) for the association between CE, T2, RLE portal venous and RLE delayed as dependent variables, and mHAI and fibrosis as independent variables. For sensitivity analyses we also performed these analyses also with laboratory parameters as independent variables, and derived an optimal cut-off value with highest sensitivity and specificity for the distinction between fibrosis stages 0/1 to 2 and 3 to 4 based on RLE delayed.

For all analyses, the statistical software R [42] was used, Cohen’s Kappa was based on the implementation in the irr [43] package, mixed-effects models on the lme4 [44] and the lmerT-test package [45], optimal cut-off plots and derivation on ROCR [46], and pROC [47] packages.

**Results**

**Patient cohort and laboratory results**

Out of 40 patients included in this study, N = 29 patients received a contrast-enhanced MRI scan. Their data were analyzed both for signal increase on T2-weighted images, CE alterations and RLE. The remaining N = 11 non-contrast-enhanced MRI scans were analyzed for signal alterations only on T2-weighted imaging. Patient characteristics, histopathological and MRI parameters are included in Table 2.
Liver histology

Histopathological results were available from all patients and obtained either from the RL (N = 8) or LL (N = 6) or both liver lobes (N = 26). In total, 66 biopsies were analyzed (RL: 34; LL: 32) (Table 2).

According to histopathological staging of liver fibrosis, 8/66 biopsies obtained from the LL or RL were classified as liver cirrhosis (stage 4), 21/66 biopsies showed a significant to severe stage of fibrosis (stage 2 or 3) and 37/66 no or minor fibrotic tissue alterations (stage 0 or 1) (Table 2).

The highest mHAI of this patient cohort was 9 of 18 points and found in 1 biopsy. 28 biopsies (RL N = 15; LL N = 13) were classified having an elevated mHAI, based on the cut-off value ≥ 3.

We found interdependencies in the data for measurements in the RL and LL for both fibrosis stage and mHAI, quantified with a Spearman correlation coefficient between LL and RL of r = 0.70 for fibrosis and r = 0.71 for mHAI (Data are illustrated in S1 Table).

Relative liver enhancement in portal venous and delayed phase images

The mean ± standard deviation (SD) of RLE in the portal venous phase was 69.1 ± 25.3% (RL) and 62.7 ± 24.8% (LL), and 34.0 ± 36.8% (RL) and 33.1 ± 37.6% (LL) in the delayed phase imaging, respectively (Table 2).
Association between relative liver enhancement and histological stages of fibrosis

The associations between RLE of the portal venous and delayed phase imaging and fibrosis stages are depicted in Fig 3. Using regression analysis, no significant associations of the portal venous phase RLE and stages of fibrosis were observed (p ≥ 0.72) (Table 3).

However, there was a consistent positive association between the delayed phase RLE and fibrosis stage. This association was also found significant based on regression analysis [fibrosis stage 2: \( \beta = 35.13; 95\%\text{-CI} (11.35; 58.87); p = 0.007 \); fibrosis stage 3/4: \( \beta = 69.24; 95\%\text{CI} (45.77; 92.75); p < 0.001 \)] (Table 3).

Table 3. Association between imaging parameters (CE, T2, RLE portal venous, RLE delayed) and histological inflammation and fibrosis based on mixed-effects models.

|                | Contrast-enhancement\(^1\) (N = 48) | T2 hyperintensity\(^1\) (N = 66) | RLE pvp\(^2\) (N = 48) | RLE dp\(^2\) (N = 48) |
|----------------|-------------------------------------|---------------------------------|-----------------------|----------------------|
|                | OR (p-value)                        | Regression coefficient \(\beta\) (p-value) |                       |                      |
| **Inflammation**\(^3\) |                                    |                                 |                       |                      |
| mHAI 0–2       | 0.24 (0.10)                         | 0.38 (0.40)                     | 4.16 (0.59)           | -8.54 (0.40)         |
| mHAI 3–6       | 0.22 (0.11)                         | 0.32 (0.33)                     | -2.60 (0.74)          | -13.22 (0.22)        |
| mHAI ≥7        | 0.28 (0.33)                         | 0.84 (0.93)                     | 25.5 (0.04)           | 14.64 (0.45)         |
| **Fibrosis**\(^4\) |                                    |                                 |                       |                      |
| Stage 1        | 1.12 (0.92)                         | 1.74 (0.76)                     | -4.20 (0.72)          | 9.19 (0.39)          |
| Stage 2        | 1.62 (0.71)                         | 4.34 (0.46)                     | 4.27 (0.75)           | 35.13 (0.007)        |
| Stage 3 and 4  | 8.79 (0.12)                         | 532.46 (0.13)                   | -0.23 (0.99)          | 69.24 (<0.001)       |

Abbreviations: mHAI, modified hepatic activity index; T2, T2-weighted image; CE, contrast-enhancement; RLE, relative liver enhancement; OR, Odds ratio; \(\beta\), regression coefficient; pvp, portal venous phase; dp, delayed-phase.

\(^1\) based on mixed-effect logistic regression models with patient as random intercept, imaging (CE, T2) as dependent variables, each histology parameter as independent variable.

\(^2\) based on mixed-effects linear regression models with patient as random intercept, RLE (portal venous phase, delayed phase) as dependent variables.

\(^3\) Reference is mHAI grade 0–2

\(^4\) Reference is fibrosis stage 0.

Bold font: significant p-value ≤ 0.05.

https://doi.org/10.1371/journal.pone.0193929.t003
Sensitivity analyses

Based on the significant results for RLE delayed, we derived an optimal cut-off value of 66.6%, with a sensitivity of 0.833 and a specificity of 0.972 for distinguishing between fibrosis grade 0–2 and fibrosis grade 3–4. A higher sensitivity of 0.917 can only be obtained by compromising specificity to 0.583 based on a cut-off of 26.43% for the RLE delayed (Fig 4). Overall, an area under the curve (AUC) value of 0.92 showed that the RLE delayed performed well in distinguishing between these fibrosis stage groups.

Relative liver enhancement and histopathological grade of inflammation

Fig 5 depicts the RLE for activity of inflammation assessed by mHAI grade < 3, ≥ 3 and ≤ 6, and ≥ 7 points. Linear regression revealed a significant association of the portal venous phase RLE with mHAI grade ≥ 7 points [β = 25.5; 95% CI (2.53; 48.62); p = 0.04]. No association was observed for portal venous phase RLE with mHAI grade ≤ 6 (p ≥ 0.74) or mHAI and delayed phase RLE (p ≥ 0.45) (Table 3). Due to the small sample size with mHAI grade ≥ 7 points (RL N = 5; LL N = 3) (Table 2), further sensitivity analyses were not performed.

Inter-rater agreement for quantification of relative liver enhancement

The quantification of RLE showed excellent inter-rater agreement both in the RL and LL. The inter-rater agreement of the portal venous phase was (Pearson correlation coefficient, 95% confidence interval): RL [r = 0.96 (0.10–0.98)], LL [r = 0.90 (0.77–0.96)]. The IRR for quantification of the RLE in the delayed phase was: RL [r = 0.98 (0.96–0.99)]; LL [r = 0.96 (0.90–0.98)], respectively. A Bland-Altman plot of both observers showed a bias of -2.05 [95%
limits of agreement (-20.94 to 16.84) and a bias of -1.79 [95% limits of agreement (-20.04 to 16.47)] for the portal venous and delayed RLE, respectively (Fig 6). For delayed phase RLE, the Bland-Altman plot depicts a wider distribution of data points in RLE measurements over 60%, while for lower RLE data points are closer to each other.

**T2 signal and CE alterations**

Visual aspects of T2 hyperintense signal alterations on areas corresponding to the area of liver biopsy were found in 33 (RL: 19; LL: 14) of 66 histopathologically analyzed areas. A visible increase of contrast enhancement in delayed phase imaging was detected in 26 (RL: 14; LL: 12) of 66 areas (Table 2). In total, 7 out of 114 measurements were binary rated by the two operators and independently analyzed by the third reviewer. Binary ratings were predominantly found for T2 signal of the RL (N = 4) and LL (N = 2). Only one binary rating resulted in assessment of CE alterations (RL = 1; LL = 0). Images with binary ratings were reviewed by a third rater and decided positive in all cases. The IRR for detection of T2 hyperintense areas within
the biopsy location was 'substantial' for the RL [Kappa = 0.77; 95% CI (0.548–0.981)] and 'almost perfect' for the LL [Kappa = 0.87; 95% CI (0.699–1.0)]. The IRR for detection of CE was 'almost perfect' for the RL [Kappa = 0.92; 95% CI (0.766–1.0)] and the LL [Kappa = 1.0; 95% CI (1.0–1.0)].

**Association of imaging parameters (CE, T2 signal) with histological inflammation and fibrosis**

Using mixed-effects models to assess the association of visual aspects of T2 signal and CE, there was no statistically significant relationship between these imaging parameters and histopathological stages of fibrosis or mHAI grades (p ≥ 0.1 for all analyses). Details are listed in Table 3.

**Association of imaging parameters (CE, T2 signal, and RLE) and laboratory results**

No association of laboratory parameters (Bilirubin, ALT, AST, γGT, AP, and IgG) and imaging parameters (T2, CE, and RLE) was found (S2 Table).

**Discussion**

In PSC it is becoming increasingly recognized that non-invasive markers of liver inflammation and fibrosis are urgently needed for the assessment of disease progression and treatment response, particularly with respect to upcoming clinical trials [11]. This is the first study to analyze the association between T2 signal intensity, gadolinium-based contrast-enhanced multiphase MRI, and the histological severity of liver parenchymal inflammation and fibrosis in patients with PSC.

We propose that the relative liver enhancement in the delayed phase might serve as a valid marker for liver fibrosis in PSC and that it is superior to the visual assessment of T2 signal intensity and CE. According to the data in the present study a strong positive association between histological staging of fibrosis and delayed phase RLE can be observed, but not with portal venous phase RLE. This association is not observed for visual assessment of T2 signal intensity and CE. Peripheral wedge-shaped areas of T2 hyperintensity are frequently found in T2-weighted MRI of PSC livers. Until today no consensus exists whether inflammation or fibrosis contributes more to this finding. One study conducted on PSC patients found correlations of T2 signal intensity with histopathological signs of inflammation of hilar bile ducts, which causes obstruction of the venous and lymphatic drainage on biopsy examination [1]. However, the authors of this study also admitted that increased T2 signal is also observed in areas of confluent fibrosis or cirrhosis. The fact that T2 signal seems to be influenced by fibrosis and also by inflammation could be one more reason that findings obtained in this study lack a statistically significant association with stages of fibrosis or the modified hepatitis activity score.

A major strength of our study is the use of an extracellular gadolinium-based contrast agent. Correlations of a hepatocyte-specific (gadoxetic acid) contrast enhancement and liver fibrosis have been reported previously and describe a negative correlation of contrast enhancement and fibrosis stage (r = -0.79, p < 0.001) [48], (r = -0.545, p < 0.0001) [49]. However, the administration of a hepatocyte-specific contrast agent might additionally be useful in the setting of hepatocellular malignancy detection and evaluation of the biliary tree using T1 MRC [38], but at the disadvantage of increased material costs and acquisition times compared to conventional extracellular GBCA-enhanced MRI. These disadvantages of additional cost and
time also apply for MRE, which has been shown to be able to distinguish between different stages of fibrosis and has therefore been proposed for evaluation of prognosis in patients with PSC [50].

In contrast to liver fibrosis, a weaker but significant association of portal venous RLE and mHAI grades ≥ 7 points was observed in this study cohort, whereas no associations of delayed RLE and mHAI grades were evident. The weak correlation of portal venous RLE and inflammation could possibly be influenced by hemodynamic changes of chronic liver disease (e.g., hepatic fibrosis or cholestasis in PSC patients) superimposed on the effects of portal venous phase MRI characteristics.

Our findings of delayed phase RLE are in line with the results of a previous multiphase GBCA-enhanced MRI study of patients with chronic and active hepatitis by Martin et al. [27]. In this study, arterial and delayed phase images were scored by three readers using feature categorization templates to quantify enhancement patterns. They found a high correlation of delayed phase liver enhancement scores with histopathological Scheuer stages of fibrosis (r = 0.96), but no association with histopathological Scheuer grades of inflammation (r = 0.071). However, enhancement patterns of the portal venous phase were not included in this study, and data obtained by the three readers were averaged despite only ‘fair’ agreement (Kappa 0.35 to 0.386). We believe, that the quantification of enhancement via RLE is more reliable than the quantification method applied by Martin et al. [27] with regard to IRR, which was considered ‘almost perfect’ on correlation analysis of this study. Visual quantification of T2 signal and CE reached slightly less favorable results.

To our knowledge, an association of extracellular GBCA portal venous phase enhancement and mHAI grades of liver inflammation have not yet been described. However, a recent study by Chen et al. [51] of N = 58 cases with chronic hepatitis found a significant association of gadoteric acid DCE-MRI derived parameters arterial fraction (p = 0.033) and area under the curve (p = 0.047) with mHAI grades on liver histology [51]. Another study by Puustinen et al. [52] reported the feasibility of phosphorus-31 (31P) magnetic resonance spectroscopy for detection of inflammation in N = 12 autoimmune hepatitis patients. A significant positive correlation of phosphoenolpyruvate was observed with METAVIR grades of inflammation (r = 0.746; p = 0.005).

Recent studies published on PSC patients have mainly focused on liver function and not fibrosis. These studies evaluated T1 mapping and DCE-MRI. The reported T1 relaxation time decrease correlated with serum liver functional tests (AP, γGT, AST, ALT) as well as with the clinical scores Model for End-Stage Liver Disease (MELD) and PSC Mayo Risk Score [53]. Several other studies assessed the efficacy of different gadoteric acid-enhanced MRI-based liver function indices in correlation with the indocyanine green (ICG) clearance (r = −0.354 to −0.574; p < 0.001) [54]. Another group evaluated the total and segmental liver function and volume by means of hepatocyte-specific DCE-MRI in a small cohort of N = 12 PSC patients. Authors reported significant correlations between biliary obstruction and segmental liver functional parameters (HEF Spearman’s rho -0.24; p < 0.05) and input relative blood flow (irBF Spearman’s rho -0.45; p < 0.05) [21].

Limitations of this study include the small number of PSC patients, especially those with histological Scheuer fibrosis staging of 3 or 4, and its single center set-up. In particular, the weakly significant correlation of portal venous RLE and higher mHAI scoring points must be interpreted with care, as this result was obtained with relatively small observations (mHAI ≥ 7; RL N = 5; LL N = 3). Before determining cut-off values for diagnostic purposes, larger follow-up multi center studies are needed to validate our preliminary observations. Additionally, liver biopsies were obtained up to 6 months before or after MRI scans, which could make exact relocation of the biopsy side difficult even with documentation in the
laparoscopically performed procedure. An MRI-guided percutaneous biopsy or an even more precise upcoming technique of real-time MRI/Ultrasound (US) fusion-guided biopsy, which has already found application in prostate cancer would be of interest for future studies [55–57]. Lastly, two pathologists assessed liver histology by consensus, making it impossible to consider the effect of the IRR.

Conclusion
The results of our study indicate the potential usefulness of extracellular GBCA enhancement, quantified by means of the RLE, for the staging of hepatic fibrosis and the identification of higher grades of hepatic inflammation in patients with PSC. Its easy application and use of existing equipment means this technique could be an interesting addition to the current imaging armamentarium of non-invasive fibrosis measurements and evaluation of disease activity, if validated in larger cohorts.

Supporting information
S1 Table. Intraindividual correlation of fibrosis stages and mHAI grades in patients with bilateral liver biopsy (N = 26).
(DOCX)
S2 Table. Laboratory parameters and their association with MRI parameters (T2, CE, RLE).
(DOCX)

Acknowledgments
Ansgar W. Lohse and Christoph Schramm were supported by the Deutsche Forschungsgemeinschaft (DFG) (SFB841 and KFO306). Christoph Schramm was supported by the Helmut and Hannelore Greve Foundation and the YAEL-Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions
Conceptualization: Sarah Keller, Jin Yamamura.
Data curation: Sarah Keller, Sören A. Weidemann, Till Krech, Jin Yamamura.
Formal analysis: Sarah Keller, Annette Aigner.
Investigation: Sarah Keller, Sören A. Weidemann, Till Krech, Jin Yamamura.
Methodology: Sarah Keller, Annette Aigner, Arnoud Meijer, Till Krech, Christoph Schramm, Jin Yamamura.
Project administration: Christoph Schramm, Jin Yamamura.
Resources: Arnoud Meijer.
Supervision: Anne C. Kim, Ansgar W. Lohse, Gerhard Adam, Christoph Schramm, Jin Yamamura.
Validation: Annette Aigner, Roman Zenouzi, Anne C. Kim, Jin Yamamura.
Visualization: Sarah Keller.
Writing – original draft: Sarah Keller.
Writing – review & editing: Roman Zenouzi, Anne C. Kim, Arnoud Meijer, Christoph Schramm, Jin Yamamura.

References

1. Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology. 2009; 50(2):526–37. https://doi.org/10.1002/hep.23024 PMID: 19575454.

2. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013; 382 (9904):1587–99. https://doi.org/10.1016/S0140-6736(13)60096-3 PMID: 23810223.

3. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011; 53(5):1590–9. https://doi.org/10.1002/hep.24247 PMID: 21351115.

4. Ponsioen CY, Vrouwenraets SM, Prawirodjo W, Rajaram R, Rauws EA, Mulder CJ, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002; 51(4):562–6. PMID: 12235081.

5. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol. 2007; 102(1):107–14. https://doi.org/10.1111/j.1572-0241.2006.00872.x PMID: 17037993.

6. Bambha K, Kim WR, Talwalkar J, Tortorini M, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003; 125(5):1364–9. PMID: 14598252.

7. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults: a population-based analysis. Am J Gastroenterol. 2007; 102(2):1042–9. https://doi.org/10.1111/j.1572-0241.2007.01103.x PMID: 17313496.

8. Ponsioen CY. Diagnosis, Differential Diagnosis, and Epidemiology of Primary Sclerosing Cholangitis. Dig Dis. 2015; 33 Suppl 2:134–9. https://doi.org/10.1159/000440823 PMID: 26640943.

9. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. Journal of hepatology. 2009; 51(2):237–67. https://doi.org/10.1016/j.jhep.2009.04.009 PMID: 19501929.

10. Schramm C, Eaton J, Ringel Ki, Venkatesh S, Yamamura J, IPSCSG MRIwgot. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology. 2017. https://doi.org/10.1002/hep.29293 PMID: 28555945.

11. Ponsioen CY, Chapman RW, Chazouilleres O, Hirschfield GM, Karlsen TH, Lohse AW, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology. 2016; 63(4):1357–67. https://doi.org/10.1002/hep.28256 PMID: 26418478.

12. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97(10):2614–8. https://doi.org/10.1111/j.1572-0241.2002.06036.x PMID: 12385448.

13. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993; 118(2):96–8. PMID: 8416324.

14. Schramm C, Eaton J, Ringel Ki, Venkatesh S, Yamamura J, IPSCSG MRIwgot. Recommendations on the use of MRI in PSC-A position statement from the International PSC study group. Hepatology. 2017. https://doi.org/10.1002/hep.29293 PMID: 28555945.

15. Manduca A, Oliphant TE, Dresner MA, Mahowald JL, Kruse SA, Amromin E, et al. Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal. 2001; 5(4):237–54. PMID: 11731304.

16. Rouviere O, Yin M, Dresner MA, Rossman PJ, Burgart LJ, Fidler JL, et al. MR elastography of the liver: preliminary results. Radiology. 2006; 240(2):440–5. https://doi.org/10.1148/radiol.2402050606 PMID: 16864671.

17. Yin M, Talwalkar JA, Glaser K, Manduca A, Grimm RC, Rossman P, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007; 5(10):1207–13.e2. https://doi.org/10.1016/j.cgh.2007.06.012 PMID: 17916548.

18. Fulcher AS, Turner MA, Franklin KJ, Shiftman RL, Luketic VA, et al. Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study. Radiology. 2000; 215(1):71–80. https://doi.org/10.1148/radiol.215.1.r00ap2071 PMID: 10751470.
19. Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010; 256(2):387–96. https://doi.org/10.1148/radiol.10091953 PMID: 20656832.

20. Angulo P, Pearce DH, Johnson CD, Henry JJ, LaRusso NF, Petersen BT, et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. Journal of hepatology. 2000; 33(4):520–7. PMID: 11059855.

21. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jacobsson H, Hagen K, et al. Dynamic gadosectate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. Journal of magnetic resonance imaging: JMRI. 2014; 39(4):879–86. https://doi.org/10.1002/jmri.24250 PMID: 24134247.

22. Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases. Journal of hepatology. 2014. https://doi.org/10.1016/j.jhep.2014.10.014 PMID: 25457198.

23. Martin DR, Seibert D, Yang M, Salmon K, Frick MP. Reversible heterogeneous arterial phase liver perfusion associated with transient acute hepatitis: findings on gadolinium-enhanced MRI. Journal of magnetic resonance imaging: JMRI. 2004; 20(5):838–42. https://doi.org/10.1002/jmri.20192 PMID: 15503331.

24. Kanematsu M, Danet MI, Leonardou P, Mastroпасqua M, Mosetti MA, Braga L, et al. Early heterogeneous enhancement of the liver: magnetic resonance imaging findings and clinical significance. Journal of magnetic resonance imaging: JMRI. 2004; 20(2):242–9. https://doi.org/10.1002/jmri.20097 PMID: 15269949.

25. Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases. Journal of hepatology. 2014. https://doi.org/10.1016/j.jhep.2014.10.014 PMID: 25457198.

26. Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology. 2003; 229(2):409–14. https://doi.org/10.1148/radiol.229202128 PMID: 12970464.

27. Martin DR, Lauenstein T, Kalb B, Lurie C, Kitajima H, Sharma P, et al. Liver MRI and histological correlates in chronic liver disease on multiphase gadolinium-enhanced 3D gradient echo imaging. Journal of magnetic resonance imaging: JMRI. 2012; 36(2):422–9. https://doi.org/10.1002/jmri.23668 PMID: 22566123.

28. Nilsson H, Blomqvist L, Douglas L, Nordell A, Janczewsk a I, Naslund E, et al. Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. The British journal of radiology. 2013; 86(1026):20120653. https://doi.org/10.1259/bjr.20120653 PMID: 23403453.

29. Faria SC, Ganesan K, Mwangi I, Shiemorteza M, Viamonte B, Mazhar S, et al. MR imaging of liver fibrosis: current state of the art. Radiographics. 2009; 29(6):1615–35. https://doi.org/10.1148/rg. 296095512 PMID: 19959511.

30. Denzer U, Arnoldy A, Kanzler S, Galle PR, Dienes HP, Lohse AW. Prospective randomized comparison of mini-laparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol. 2007; 41(1):103–10. https://doi.org/10.1097/01.mcg.0000225612.86846.82 PMID: 17198072.

31. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. Journal of hepatology. 1991; 13(3):372–4. PMID: 1808228.
38. Nolz R, Asenbaum U, Schoder M, Wibmer A, Einspieler H, Prusa AM, et al. Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography. Clin Radiol. 2014; 69(5):499–508. https://doi.org/10.1016/j.crad.2013.12.008 PMID: 24630133.

39. Fleiss JL, C J, Everitt BS. Large sample standard errors of kappa and weighted kappa. Psychological Bulletin. 1969; 72:323–7.

40. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159–74. PMID: 843571.

41. Portney L, Watkins M. Foundations of clinical research: application to practice. Upper Saddle River, NJ: Prentice Hall; 1999.

42. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.

43. Gamer M, Lemon J, Fellows I, Singh P. irr: Various Coefficients of Interrater Reliability and Agreement. R package version 0.84. Internet resource: http://CRAN.R-project.org/package=irr Verified April. 2012;10: 2013.

44. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. 2015; 67(1):48. Epub 2015-10-07. https://doi.org/10.18637/jss.v067.i01

45. Kuznetsova A, Brockhoff B, Christensen RHB. lmerTest: Tests in Linear Mixed Effects Models. 2016. 2.0–33 ed2016. p. Different kinds of tests for linear mixed effects models as implemented in 'lme4' package are provided. The tests comprise types I—III F tests for fixed effects, LR tests for random effects. The package also provides the calculation of population means for fixed factors with confidence intervals and corresponding p-values. Finally the backward elimination of non-significant effects is implemented.

46. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCr: visualizing classifier performance in R. Bioinformatics. 2005; 21(20):7881.

47. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S- to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. https://doi.org/10.1186/1471-2105-12-77 PMID: 21414208.

48. Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging—p reliminary observations. Radiology. 2011; 259(1):142–50. https://doi.org/10.1148/radiol.10100621 PMID: 21248234.

49. Jang YJ, Cho SH, Bae JH, Kim GC, Ryeom H, Kim HJ, et al. Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI. Ann Hepatol. 2013; 12(6):926–34. PMID: 24114823.

50. Eaton JE, Dzyubak B, Venkatesh SK, Smyrk TC, Gores GJ, Ehman RL, et al. Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol. 2016; 31(6):1184–90. https://doi.org/10.1111/jgh.13263 PMID: 26691631.

51. Chen BB, Hsu CY, Yu CW, Kao JH, Lee HS, Liang PC, et al. Hepatic necro-inflammation and elevated liver enzymes: evaluation with MRI perfusion imaging with gadoxetic acid in chronic hepatitis patients. Clin Radiol. 2014; 69(5):473–80. https://doi.org/10.1016/j.crad.2013.12.003 PMID: 24556486.

52. Puustinen L, Hakkarainen A, Kivisaari R, Boyd S, Nieminen U, Farkkila M, et al. (31)Phosphorus magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis. Scand J Gastroenterol. 2017; 52(8):886–92. https://doi.org/10.1080/00365521.2017.1315738 PMID: 28415898.

53. Hinrichs H, Hinrichs JB, Gutberlet M, Lenzen H, Raatschen HJ, Wacker F, et al. Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC). Eur Radiol. 2015. https://doi.org/10.1007/s00330-015-3913-y PMID: 26205638.

54. Yoneyama T, Fukukura Y, Kamimura K, Takumi K, Umanodan A, Ueno S, et al. Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function. Eur Radiol. 2014; 24(4):857–65. https://doi.org/10.1007/s00330-013-3086-5 PMID: 24365768.

55. Maxeiner A, Fischer T, Stephan C, Cash H, Slowinski T, Kilic E, et al. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients]. Aktuelle Urol. 2014; 45(3):187–203. https://doi.org/10.1055/s-0034-1375682 PMID: 24902069.

56. Maxeiner A, Stephan C, Durmus T, Slowinski T, Cash H, Fischer T. Added Value of Multiparametric Ultrasonography in Magnetic Resonance Imaging and Ultrasonography Fusion-guided Biopsy of the Prostate in Patients With Suspicion for Prostate Cancer. Urology. 2015; 86(1):108–14. https://doi.org/10.1016/j.urology.2015.01.053 PMID: 26142993.
57. Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013; 64(5):713–9. https://doi.org/10.1016/j.eururo.2013.05.059 PMID: 23787357.